Free Trial

OncoSec Medical (ONCSQ) Competitors

ONCSQ vs. CLVR, EFTR, PXMD, ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, AMPE, and ACABW

Should you be buying OncoSec Medical stock or one of its competitors? The main competitors of OncoSec Medical include Clever Leaves (CLVR), eFFECTOR Therapeutics (EFTR), PaxMedica (PXMD), 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Ampio Pharmaceuticals (AMPE), and Atlantic Coastal Acquisition Corp. II (ACABW). These companies are all part of the "pharmaceutical products" industry.

OncoSec Medical vs. Its Competitors

OncoSec Medical (NASDAQ:ONCSQ) and Clever Leaves (NASDAQ:CLVR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

OncoSec Medical has a beta of -19.7, indicating that its share price is 2,070% less volatile than the S&P 500. Comparatively, Clever Leaves has a beta of 3440.04, indicating that its share price is 343,904% more volatile than the S&P 500.

Company Net Margins Return on Equity Return on Assets
OncoSec MedicalN/A N/A N/A
Clever Leaves N/A N/A N/A

In the previous week, OncoSec Medical's average media sentiment score of 0.00 equaled Clever Leaves'average media sentiment score.

Company Overall Sentiment
OncoSec Medical Neutral
Clever Leaves Neutral

Clever Leaves has higher revenue and earnings than OncoSec Medical.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OncoSec MedicalN/AN/A-$34.18MN/AN/A
Clever Leaves$17.42M0.00-$17.90M-$11.31N/A

6.9% of Clever Leaves shares are owned by institutional investors. 1.3% of OncoSec Medical shares are owned by insiders. Comparatively, 8.2% of Clever Leaves shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Clever Leaves beats OncoSec Medical on 5 of the 5 factors compared between the two stocks.

Get OncoSec Medical News Delivered to You Automatically

Sign up to receive the latest news and ratings for ONCSQ and its competitors with MarketBeat's FREE daily newsletter.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ONCSQ vs. The Competition

MetricOncoSec MedicalPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1K$839.03M$5.60B$9.11B
Dividend YieldN/A4.84%5.24%4.02%
P/E RatioN/A1.1727.9620.25
Price / SalesN/A241.37430.5799.61
Price / CashN/A17.6937.4658.16
Price / BookN/A6.528.045.49
Net Income-$34.18M-$23.68M$3.18B$250.27M

OncoSec Medical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ONCSQ
OncoSec Medical
N/AN/AN/AN/A$1KN/A0.0040
CLVR
Clever Leaves
N/A$0.00
flat
N/AN/A$1K$17.42M0.00560
EFTR
eFFECTOR Therapeutics
0.0787 of 5 stars
$0.00
flat
N/A-99.4%$1K$3.55M0.0010Gap Down
PXMD
PaxMedica
N/A$0.00
flat
N/AN/A$1KN/A0.002News Coverage
ATNFW
180 Life Sciences
N/A$0.01
+7.5%
N/A-2.4%$0.00N/A0.007Positive News
Gap Down
LBPSW
4D pharma
N/AN/AN/AN/A$0.00$522K0.00N/A
AEHAW
Aesther Healthcare Acquisition
N/A$0.01
flat
N/A-83.4%$0.00N/A0.002
AIMDW
Ainos
N/A$0.13
-13.3%
N/A+70.4%$0.00$106.21K0.0040Gap Up
ALVOW
Alvotech
N/A$1.73
+1.8%
N/A-42.1%$0.00$585.60M0.004Positive News
Gap Up
AMPE
Ampio Pharmaceuticals
N/A$0.00
-96.3%
N/A-99.9%$0.00N/A0.0020Gap Down
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.02
-0.5%
N/AN/A$0.00N/A0.0015

Related Companies and Tools


This page (NASDAQ:ONCSQ) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners